Ala Abudayyeh, MD
Department of Emergency Medicine, Division of Internal Medicine
About Dr. Ala Abudayyeh
Dr. Ala Abudayyeh is a provider in the Internal Medicine Center and a Professor in Nephrology. She is board-certified in Internal Medicine and joined MD Anderson in 2012.
Present Title & Affiliation
Primary Appointment
Professor, Section of Nephrology, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Director of Clinical Research, Section of Nephrology, The University of Texas MD Anderson Cancer Center, Houston, TX
Dual/Joint/Adjunct Appointment
Professor, Section of Nephrology, The University of Texas MD Anderson Cancer Center, Houston, Texas
Education & Training
Degree-Granting Education
| 2003 | University of Texas-Houston Medical School, Houston, Texas, US, MD |
| 1999 | Baylor University, Waco, Texas, US, Biology, BS |
Postgraduate Training
| 2009-2011 | Nephrology Fellowship, Nephrology, Baylor College of Medicine, Houston, Texas |
| 2004-2006 | Resident, Internal Medicine, Baylor College of Medicine, Houston, Texas |
| 2003-2006 | Internal Medicine Resident, Baylor College of Medicine, Houston, Texas |
Licenses & Certifications
| 2017 | Nephrology |
| 2011 | American Board of Internal Medicine |
| 2006 | Texas Medical Board |
| null | Washington State Department of Health |
| null | Louisiana State Board of Medical Examiners |
| null | Mississippi State Board of Medical Licensure |
| null | Oklahoma State Board of Medical Licensure |
| null | Alabama Board of Medical Examiners |
| null | Tennessee Board of Medical Examiners |
| null | Georgia Composite Medical Board |
| null | Arizona Board of Medical Examiners |
| null | Florida Board of Medicine |
Experience & Service
Faculty Academic Appointments
Associate Professor, Internal Medicine, Houston Methodist Hospital, HOUSTON, TX, 2018
Associate Professor, Section of Nephrology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2017 - 2023
Assistant Professor, Section of Nephrology, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2013 - 2017
Visiting Professor, Institute of Biosciences and Technology, Texas A&M Health Science Center, Houston, TX, 2012 - 2014
Assistant Professor, General Internal Medicine, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2012 - 2013
Administrative Appointments/Responsibilities
Member to the Cancer Survivorship Research Advisory Workgroup, Cancer Survivorship Research Advisory Workgroup, The University of Texas MD Anderson Cancer Center, houston, TX, 2021 - Present
Director of Clinical Research, Section of Nephrology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2020 - Present
Other Professional Positions
Founding member, American Society of Onconephrology, houston, TX, 2021 - Present
Co-Author, UptoDate-Kidney disease following hematopoietic cell transplantation, HOUSTON, TX, 2020
Physician, Associated Family Medicine, Orlando, FL, 2006 - 2008
Extramural Institutional Committee Activities
Member of Committee, Amyloid working group, The University of Texas MD Anderson Cancer Center, 2019
Member of executive Committee, Toxicity Executive Committee, The University of Texas MD Anderson Cancer Center, 2019
member, Division of Internal Medicine Research committee, The University of Texas MD Anderson Cancer Center, 2019 - Present
Co-Chair CPI induced Renal toxcicity, DoIM TOXICITIES RESEARCH SUB GROUP, The University of Texas MD Anderson Cancer Center, 2019
member, Hemodialysis Steering committee, The University of Texas MD Anderson Cancer Center, 2015 - Present
Member, General Internal Medicine/Nephrology: Quality Improvement Sub-Committee, The University of Texas MD Anderson Cancer Center, 2013
Member, Department of General Internal Medicine Gender Inclusiveness Committee, The University of Texas MD Anderson Cancer Center, 2013
Editorial Activities
Editor, Clinical Nephrology and Theraputics, 2016 - Present
Editorial Board Member, Journal of Onconephrology, 2016 - Present
invited Reviwers, Cytotherapy, 2016
invited Reviwer, Annals of internal Medicine, 2016
Honors & Awards
| 2021 - 2024 | FASN, American Society of Nephrology |
| 2018 | 2018 Top Performers (top 1% of providers nationally ranked by patients for their delivery of care), Centers for Medicare and Medicaid Services (CMS) and Clinician and Group Consumer Assessment of Healthcare Providers and Systems (CGCAHPS) |
| 2017 | Excellence in patient Care nominee, Division of internal Medicine MDACC |
| 2015 - 2024 | Section of Nephrology 2015 Outstanding Nephrology Faculty Award, MDACC |
| 2014 | Division of Internal Medicine faculty recognition Award, MDACC |
| 2011 | American Society of Nephrology Grant |
| 2010 | Chief, Nephrology Fellow, Baylor College of Medicine |
| 2009 | National Kidney Foundation Grant |
| 1998 - 1999 | Mortar Board National Honor Society, Membership |
| 1997 - 1999 | Gamma Beta Phi Honor Society |
| 1997 - 1999 | Alpha Chi National Honor Society |
| 1997 - 1999 | Beta - Biology Honor Society |
| 1997 - 1999 | Golden Key Honor Society |
| 1996 - 1999 | Alpha Epsilon Delta Pre-med/Pre-dent Honor Society |
| 1996 - 1999 | Dean's List, Stephen F. Austin State University |
Professional Memberships
Selected Presentations & Talks
Local Presentations
- 2024. Relevance of Mouse Models for Clinical Management of irAEs. Invited. MD Anderson Cancer Center IOTOX Symposium. Houston, Texas, US.
- 2019. CPI Induced Renal IRAE "The Unchartered Waters". Conference. Methodist. Houston, TX, US.
- 2018. Immunotherapy and renal Toxicity. Conference. Baylor College of Medicine. Houston, TX, US.
- 2018. Onconephrology. Conference. University of Texas MD Anderson Cancer Center. Houston, TX, US.
- 2018. Diabetic Nephropathy. Conference. University of Texas MD Anderson Cancer Center. Houston, TX, US.
- 2017. CKD & Cancer. Conference. Methodist. Houston, TX, US.
- 2017. Immunocompromised Population: An overlooked Pathogen. Conference. 2017 Cancer Survivorship Research Symposium titled “Cancer Survivorship Research Across Texas”. Houston, TX, US.
- 2015. BK Virus Infection in Hematopoetic Stem Cell Transplant Survivors and Renal Outcomes. Conference. University of Texas MD Anderson Cancer Center. Houston, TX, US.
- 2015. BK Virus as an Indicator of Poor Immune Recovery and Chronic Kidney Disease in Hematopoietic Stem Cell Transplants. Conference. University of Texas MD Anderson Cancer Center. Houston, TX, US.
- 2015. BK Virus Infection in Hematopoetic Stem Cell Transplant Survivors and Renal Outcomes. Conference. University of Texas MD Anderson Cancer Center. Houston, TX, US.
- 2006. Chronic inflammatory demylinating polyneuropathy (CIDP) disease and pregnancy. Conference. Baylor College of Medicine. Houston, TX, US.
Regional Presentations
- 2016. Outcomes of Stage IV Cancer Patients Receiving Dialysis at a Comprehensive Cancer Center. Conference. Divison of Internal Medicine research Retreat 2016, TX, US.
- 2015. BK Virus in Immunocompromised Population: An Overlooked Pathogen. Conference. Infectious Disease Research Meeting, US.
- 2015. BK Virus in Immunocompromised Population: An Overlooked Pathogen. Conference. Leukemia Department Research Meeting, US.
- 2015. Symptomatic BK virus is a significant predictor of chronic kidney disease and overall survival in allogeneic hematopoietic stem cell recipients. Conference. MDACC Survivorship research Symposium, US.
- 2015. BK Virus Infection in Hematopoetic Stem Cell Transplant Survivors and Renal Outcomes. Conference. Institutional Grand Rounds invited speaker, US.
- 2014. Inactivation of the Nuclear Receptor TR3 as an Important New Drug Target for Treating Renal Cell Carcinoma. Conference. Kidney Cancer Symposium, US.
- 2013. Dialysis and Palliative Medicine. Conference. Hospice and Palliative Medicine, US.
National Presentations
- 2024. BK virus and Stem cell transplant patients. Invited. ASON Onconephrology Symposium. New York, New York, US.
- 2021. CPI in kidney transplant and dialysis. Invited. Kidney Week-American Society of Nephrology, US.
- 2021. Kidney disease and stem cell transplant. Invited. Onconephrology symposium, US.
- 2020. Immune Checkpoint Inhibitor Associated Reactivation of Primary Membranous Nephropathy Responsive to Rituximab. Conference. American Society of Nephrology kidney week, US.
- 2020. Immune Checkpoint Inhibitor Induced Kidney and Cardiac Sarcoidosis. Conference. American Society of nephrology kidney week, US.
- 2020. Immune Checkpoint Inhibitor Induced p-ANCA Multiorgan Vasculitis. Conference. American Society of Nephrology, US.
- 2020. Onco-Nephrology Updates in Practice. Invited. American Society of nephrology Kidney week, US.
- 2020. CPI induced renal toxicity. Invited. Onconephrology symposium Mayo clinic, US.
- 2020. CPI induced renal toxicity. Invited. Oncologic Critical Care Research Network, US.
- 2019. Incidence of AKI in Melanoma patients treated with immune checkpoint inhibitors. American Society of Nephrology Annual Meeting. Conference. American Society of Nephrology, US.
- 2019. CPI induced renal toxcicity and kidney transplant. Invited. Onconephrology symposium at MSK, US.
- 2019. Nephrotoxicity of Chemotherapies. Invited. American society of Nephrology, US.
- 2018. CPI induced renal toxicity. Invited. Onconephrology symposium MDA, US.
- 2016. CKD as a Complication of Cancer. Invited. MD Anderson Onconephrology Symposium 2016. Houston, TX, US.
- 2016. Monoclonal Disease and the Kidney. Invited. Complex Hospitalized Patient conference in San Antonio, US.
- 2016. BK Virus Infections in HSCT Recipients. Invited. American Society for Microbiology/ICAAC. Boston, US.
- 2015. Characteristics of patients receiving dialysis at a comprehensive cancer center and outcomes". Conference. American Society of Nephrology. San Diego, CA, US.
- 2015. BK Virus as a Significant Predictor of Chronic Kidney Disease and Overall Survival in Hematopoietic Stem Cell Recipients. Invited. American Society of Nephrology (ASN) annual meeting. San Diego, US.
- 2015. Poster Finalist: Symptomatic BK virus is a significant predictor of chronic kidney disease and overall survival in allogeneic hematopoietic stem cell recipients. Conference. Survivorship research Symposium 2/2015: The University of Texas MD. Houston, US.
- 2014. “First Reported Case of Acute Tubular Necrosis Induced by Lenalidomide in a Patient with Follicular Lymphoma”. Conference. American Society of Nephrology. Atlanta, US.
- 2013. Primary Myelofibrosis Causes Glomerulopathy”. “Ipilimumab-Induced Immune-Related Nephritis. Conference. American Society of Nephrology. Atlanta, US.
International Presentations
- 2017. Malignancy-Associated ATI. Invited. ASN, US.
- 2016. Do Not Dialyze. Invited. ASCO 2016 Palliative Care in Oncology Symposium. San Francisco, US.
- 2016. Symptomatic BK Virus Infection Is Associated with Kidney Function Decline and Poor Overall Survival. Invited. 9th International Conference on Dialysis and Renal Care. London, GB.
- 2016. BK Virus in Immunocompromised Population: An Overlooked Pathogen. Invited. National Arab American Medical Association, OM.
- 2015. Symptomatic BK virus as a significant independent predictor of immune suppression and poor overall survival in allogeneic hematopoietic stem cell recipients. Conference. ASCO. Chicago, US.
- 2014. BK virus as a predictor of chronic kidney disease in hematopoietic stem cell Recipients. Highlight Presentation. Conference. ASCO. Chicago, US.
Formal Peers
- 2022. Kidney disease and stem cell transplant. Invited, US.
- 2019. Immunotherapy and Kidney Toxicity. Visiting. Houston, TX, US.
- 2019. CPI induced renal toxicity. Invited, US.
- 2019. Use of BKVCTL in Kidney transplant patients. Invited, US.
- 2018. Diabetic Nephropathy. Visiting. Houston, TX, US.
- 2016. BK Virus in Immunocompromised Population: An Overlooked Pathogen. Invited, US.
- 2015. University of Texas Medical School at Houston Nephrology research. Invited, US.
- 2014. Onconephrology. Invited. Houston, TX, US.
Grant & Contract Support
| Date: | 2020 - Present |
| Title: | Checkpoint Inhibitor Associated-Nephritis: Identifying Predictors of Immunotoxicity |
| Funding Source: | MDACC |
| Role: | Co-I |
| ID: | Division of internal medicine IOTOX RFA |
| Date: | 2020 |
| Title: | Phase II study assessing the effect of ex vivo Expanded, BKspecific CTLs in Kidney Transplant Recipients with BK Polyomavirus Infection |
| Funding Source: | Methodist Hospital |
| Role: | Co-PI |
| Date: | 2017 |
| Title: | Phase I Study of MLN0128 (NSC# 768435) in Combination with Ziv-Aflibercept (NSC# 724770) in Patients with Advanced Cancers” |
| Funding Source: | NIH/NCI |
| Role: | Collaborator |
| Date: | 2016 - 2017 |
| Title: | Early Metabolic Support as a Potential Solution to Multi-Organ Dysfunction Syndrome (MODS) During Severe Sepsis |
| Funding Source: | ICU |
| Role: | Collaborator |
| Date: | 2013 - 2015 |
| Title: | A Prospective Observational Study of Urinary Biomarkers of Nephrotoxicity in Cancer Patients Receiving Cisplatin Chemotherapy |
| Funding Source: | NIH/NCI |
| Role: | Co-PI |
| Date: | 2013 - 2014 |
| Title: | BK Virus Infection in Hematopoetic Stem Cell Transplant Survivors and Renal Outcomes |
| Funding Source: | The University of Texas MD Anderson Cancer Center |
| Role: | PI |
| Date: | 2013 - 2014 |
| Title: | Inactivation of the Nuclear Receptor TR3 as an Important New Drug Target for Treating RCC |
| Funding Source: | The University of Texas MD Anderson Cancer Center Kidney Cancer Research Program |
| Role: | PI |
| Title: | BK Virus as an Indicator of Immunosuppression and Poor Renal outcomes in Hematopoietic Stem Cell Transplant Survivors |
| Funding Source: | Clinical Innovator |
| Role: | PI |
| Title: | A Retrospective Study: Experience with Tumor Lysis Syndrome (TLS) at M. D. Anderson Cancer Center Before and After Rasburicase |
| Funding Source: | Other |
| Role: | PI |
| Title: | BK virus as an indicator of immunosuppression and poor renal outcome in Hematopoietic Stem cell transplants |
| Funding Source: | Sabin Award |
| Role: | PI |
| Title: | Prevalence of Kidney Disease and Hyponatremia in Inpatients at MD Anderson Cancer Center |
| Funding Source: | Knowledge Gap |
| Role: | PI |
| ID: | MDA |
| Title: | Ferumoxytol vs Gadolinium Based Contrast MRI for Metastatic Surveillance in Cancer patients with Advanced Chronic Kidney Disease (CKD) |
| Funding Source: | MDACC |
| Role: | PI |
| ID: | IRG |
| Title: | Ferumoxytol vs Gadolinium Based Contrast MRI for Metastatic Surveillance in Cancer patients with Advanced Chronic Kidney Disease (CKD) |
| Funding Source: | MDACC |
| Role: | Principal Investigator-MDACC |
| ID: | Division of internal Medicine research Award |
| Title: | BK Virus as an Indicator of Poor Immune Recovery and Chronic Kidney Disease in Hematopoietic Stem Cell Transplants: A Prospective Study |
| Funding Source: | IRG/MDA |
| Role: | PI |
| ID: | Institutional research grant |
| Title: | BK Virus as an Indicator of Poor Immune Recovery and Chronic Kidney Disease in Hematopoietic Stem Cell Transplants: A Prospective Study |
| Funding Source: | IRG/MDA |
| Role: | PI |
| Title: | Phase II study assessing the effect of ex vivo Expanded, BKspecific CTLs in Kidney Transplant Recipients with BK Polyomavirus Infection |
| Funding Source: | Department of Defense (DOD) |
| Role: | Co-PI |
| Title: | Prevalence of BK nephropathy post Allogeneic Stem Cell Transplant: Autopsy Evidence |
| Funding Source: | IRG/MDA |
| Role: | PI |
| Title: | BK Virus as an Indicator of Poor Immune Recovery and Chronic Kidney Disease in Hematopoietic Stem Cell Transplants: A Prospective Study |
| Funding Source: | American Society of Nephrology Career development grant |
| Role: | PI |
| Title: | BK virus as an indicator of immunosuppression and poor renal outcome in Hematopoietic Stem cell transplants |
| Funding Source: | R. Lee Clark Fellows Award |
| Role: | PI |
Selected Publications
Peer-Reviewed Articles
- Olson, AL, Li, YE, Basar, R, Banerjee, PP, Kaur, I, Abueg, G, Sylejmani, M, Uprety, N, Shrestha, R, Silva, FR, Page, VD, Champlin, RE, Kontoyiannis, DP, Chemaly, RF, Shpall, E, Moore, LW, Gaber, OA, Rezvani, K, Abudayyeh, A. Role of BK Virus CTLs in the Treatment of BK Virus–Associated Nephropathy in Kidney-Transplant and Hematopoietic Cell Transplant Recipients. Transplant Infectious Disease 28(2), 2026. e-Pub 2026. PMID: 41645606.
- Olson A, Li YE, Basar R, Banerjee P, Kaur I, Abueg G, Sylejmani M, Uprety N, Shrestha R, Silva FR, Page V, Champlin RE, Kontoyiannis DP, Chemaly RF, Shpall EJ, Moore L, Gaber OA, Rezvani K, Abudayyeh A. Role of BK Virus CTLs in the Treatment of BK Virus-Associated Nephropathy in Kidney-Transplant and Hematopoietic Cell Transplant Recipients. Transpl Infect Dis:e70178, 2026. e-Pub 2026. PMID: 41645606.
- Nieto Y, Ward JF, Hofstetter W, Rice D, Karam JA, Pisters L, Vauthey JN, Shah A, Lin JK, Johns AC, Araujo J, Tu SM, Wang J, Li J, Abudayyeh A, Thall PF, Bassett R, Barnett M, Gulbis A, Shigle TL, Ramdial J, Popat U, Qazilbash M, Jones RB, Andersson BS, Shpall EJ, Sheikh I, Pagliaro L, Campbell MT. High-Dose Chemotherapy for Multiply or Poor-Risk Relapsed Germ Cell Tumors. Clin Cancer Res 32(2):300-311, 2026. e-Pub 2026. PMID: 40853903.
- Youssef, N, Habeeb, M, Chen, H, Alhamal, Z, Mamlouk, O, Lin, Y, Page, VD, Tchakarov, A, Basu, S, Diab, A, Sharma, P, Abudayyeh, A. Infliximab for Grade III or IV Immune Checkpoint Inhibitor Nephritis Clinical and Translational Evidence. Kidney International Reports 11(1):32-42, 2026. e-Pub 2026. PMID: 41541786.
- Alasadi Y, Garcia JC, Arani N, Page V, Geng Y, Andersen CR, Tchakarov A, Kitchlu A, Mamlouk O, Abudayyeh A. Rituximab for the treatment of immune checkpoint inhibitor-induced glomerulonephritis. Clin Kidney J 19(1):sfaf373, 2026. e-Pub 2026. PMID: 41788614.
- Youssef N, Habeeb M, Chen H, Alhamal Z, Mamlouk O, Lin H, Page V, Tchakarov A, Basu S, Diab A, Sharma P, Abudayyeh A. Infliximab for Grade III or IV Immune Checkpoint Inhibitor Nephritis Clinical and Translational Evidence. Kidney Int Rep 11(1):32-42, 2026. e-Pub 2026. PMID: 41541786.
- Gupta S, Glezerman IG, Hirsch JS, Chewcharat A, Wells SL, Ortega JL, Pirovano M, Kim R, Chen KL, Jhaveri KD, Page VD, Abramson MH, Bansal A, Ghimire A, Joy MS, Abudayyeh A, Leaf DE. Intravenous Magnesium and Cisplatin-Associated Acute Kidney Injury. JAMA Oncol 11(6):636-643, 2025. e-Pub 2025. PMID: 40272825.
- Gupta S, Kaunfer SA, Chen KL, Dias JA, Vijayan A, Rajasekaran A, Prosek JM, Truong HL, Wood A, Bassil C, Renaghan AD, Shah CV, Zhang J, Glezerman I, Carlos C, Kelly K, Passero CJ, Drappatz J, Abudayyeh A, Shin DS, Sperati CJ, Yelvington BJ, Kanduri SR, Neyra JA, Edmonston D, Shirali AC, Bansal A, Geara A, Mithani Z, Ziolkowski SL, Rashidi A, Jakubowski J, Pujari A, Bond DA, Dotson E, Wall S, Patton J, Barreto JN, Herrmann SM, Sheikh MS, Baz R, Lee J, Lucchesi N, Kolman M, Rasheed MA, Afzal A, Kang D, Mahesh A, Hsu RK, Nicolaysen A, Tefera K, Schretlen C, Miller RM, Velez JC, Flannery AH, Aklilu AM, Anand S, Chandrasekhara S, Donley V, Patel A, Ni J, Krishnamurthy S, Ali R, Yilmam OA, Wells SL, Ortega JL, Green-Lingren OL, Leaf RK, Sise ME, Nayak L, LaCasce AS, Leung N, Leaf DE. Glucarpidase for treatment of high-dose methotrexate toxicity. Blood 145(17):1858-1869, 2025. e-Pub 2025. PMID: 39760780.
- Ward, K, Page, VD, Song, J, Amaram-Davila, JS, Mamlouk, O, Abudayyeh, A. Correcting hyponatraemia is associated with improved survival in hyponatraemic metastatic cancer patients. Clinical Kidney Journal 18(3), 2025. e-Pub 2025. PMID: 40052166.
- Herrmann SM, Abudayyeh A, Gupta S, Gudsoorkar P, Klomjit N, Motwani SS, Karam S, Costa E Silva VT, Khalid SB, Anand S, Kala J, Leaf DE, Murakami N, Rashidi A, Wanchoo R, Kitchlu A. Diagnosis and Management of Immune Checkpoint Inhibitor-Associated Nephrotoxicity: A Position Statement from the American Society of Onco-nephrology. Kidney Int 107(1):21-32, 2024. e-Pub 2024. PMID: 39455026.
- Gupta S, Glezerman IG, Hirsch JS, Wells SL, Chen KL, Seitter RH, Monson AE, Green-Lingren O, Jhaveri KD, Page VD, Abramson MH, Bansal A, Abudayyeh A, Leaf DE. Effect of Mannitol on Cisplatin-Associated AKI: A Target Trial Emulation. Nephrol Dial Transplant 40(2):405-408, 2024. e-Pub 2024. PMID: 39415423.
- Gupta S, Green-Lingren O, Bhimaniya S, Krokhmal A, Jacene H, Ostermann M, Chicklore S, Sprangers B, Deroose CM, Herrmann SM, Wells SL, Kaunfer SA, Ortega JL, Garcia-Carro C, Bold M, Chen KL, Sise ME, Heidari P, Pak WLW, Lee MD, Beckerman P, Eshet Y, Hsu RK, Hernandez Pampaloni M, Rashidi A, Avril N, Donley V, Mithani Z, Kuker R, Awiwi MO, Wang MX, Shah SI, Weintraub MD, Schoder H, Chowdhury RB, Seethapathy H, Reynolds KL, Soler MJ, Abudayyeh A, Glezerman I, Leaf DE. F18-FDG PET imaging as a diagnostic tool for immune checkpoint inhibitor-associated acute kidney injury. J Clin Invest 134(18), 2024. e-Pub 2024. PMID: 39115940.
- Kitchlu A, Silva VTCE, Anand S, Kala J, Abudayyeh A, Inker LA, Rosner MH, Karam S, Gudsoorkar P, Gupta S, Chen S, Klomjit N, Leung N, Milanez T, Motwani SS, Khalid SB, Srinivasan V, Wanchoo R, Beumer JH, Liu G, Tannir NM, Orchanian-Cheff A, Geng Y, Herrmann SM. Assessment of GFR in Patients with Cancer: A Statement from the American Society of Onco-Nephrology. Clin J Am Soc Nephrol 19(8):1061-1072, 2024. e-Pub 2024. PMID: 38848131.
- Motwani SS, Abudayyeh A. Are Antiemetics the Next Therapeutic Strategy against Cisplatin-Associated Acute Kidney Injury?. Kidney360 5(8):1067-1068, 2024. e-Pub 2024. PMID: 39207890.
- Kitchlu A, Silva VTCE, Anand S, Kala J, Abudayyeh A, Inker LA, Rosner MH, Karam S, Gudsoorkar P, Gupta S, Chen S, Klomjit N, Leung N, Milanez T, Motwani SS, Khalid SB, Srinivasan V, Wanchoo R, Beumer JH, Liu G, Tannir NM, Orchanian-Cheff A, Geng Y, Herrmann SM. Assessment of GFR in Patients with Cancer Part 2: Anticancer Therapies-Perspectives from the American Society of Onco-Nephrology (ASON). Clin J Am Soc Nephrol 19(8):1073-1077, 2024. e-Pub 2024. PMID: 39316409.
- Hanif, IH, Abdelrahim, S, Al Shaarani, M, Lu, H, Ahmad, R, Goswami, S, Abudayyeh, A. Immune Checkpoint Therapy–Induced Lupus Nephritis. Kidney International Reports 9(5):1534-1537, 2024. e-Pub 2024. PMID: 38707799.
- Gupta S, Glezerman IG, Hirsch JS, Chen KL, Devaraj N, Wells SL, Seitter RH, Kaunfer SA, Jose AM, Rao SP, Ortega JL, Green-Lingren O, Hayden R, Bendapudi PK, Chute DF, Sise ME, Jhaveri KD, Page VD, Abramson MH, Motwani SS, Xu W, Sehgal K, Reynolds KL, Bansal A, Abudayyeh A, Leaf DE. Derivation and external validation of a simple risk score for predicting severe acute kidney injury after intravenous cisplatin: cohort study. BMJ 384:e077169, 2024. e-Pub 2024. PMID: 38538012.
- Shatila, M, Eshaghi, F, Thomas, A, Kuang, AG, Shah, JS, Zhao, B, Naz, S, Sun, M, Fayle, S, Jin, J, Abudayyeh, A, Sheshadri, A, Palaskas, NL, Franco Vega, M, Gaeta, MS, Thomas, AS, Zhang, HC, Wang, Y. Practice Changes in Checkpoint Inhibitor-Induced Immune-Related Adverse Event Management at a Tertiary Care Center. Cancers 16(2), 2024. e-Pub 2024. PMID: 38254858.
- Parvathareddy, V, Selamet, U, Sen, AA, Mamlouk, O, Song, J, Page, VD, Abdelrahim, M, Diab, A, Hassan, NA, Abudayyeh, A. Infliximab for Treatment of Immune Adverse Events and Its Impact on Tumor Response. Cancers 15(21), 2023. e-Pub 2023. PMID: 37958355.
- Parvathareddy V, Selamet U, Sen AA, Mamlouk O, Song J, Page VD, Abdelrahim M, Diab A, Abdel-Wahab N, Abudayyeh AA. Infliximab for Treatment of Immune Adverse Events and Its Impact on Tumor Response. Cancer, 2023. e-Pub 2023.
- Krueger CK, Bruno JJ, Tverdek FP, Hernandez M, Abudayyeh A. Aminoglycoside Pharmacokinetics in Critically Ill Patients Undergoing Continuous Renal Replacement Therapy. Ann Pharmacother 57(6):10600280221120600, 2023. e-Pub 2022. PMID: 36062536.
- Fa'ak F, Buni M, Falohun A, Lu H, Song J, Johnson DH, Zobniw CM, Trinh VA, Awiwi MO, Tahon NH, Elsayes KM, Ludford K, Montazari EJ, Chernis J, Dimitrova M, Sandigursky S, Sparks JA, Abu-Shawer O, Rahma O, Thanarajasingam U, Zeman AM, Talukder R, Singh N, Chung SH, Grivas P, Daher M, Abudayyeh A, Osman I, Weber J, Tayar JH, Suarez-Almazor ME, Abdel-Wahab N, Diab A. Selective immune suppression using interleukin-6 receptor inhibitors for management of immune-related adverse events. J Immunother Cancer 11(6), 2023. e-Pub 2023. PMID: 37328287.
- Awiwi MO, Abudayyeh A, Abdel-Wahab N, Diab A, Gjoni M, Xu G, Vikram R, Elsayes K. Imaging features of immune checkpoint inhibitor-related nephritis with clinical correlation: a retrospective series of biopsy-proven cases. Eur Radiol 33(3):2227-2238, 2023. e-Pub 2022. PMID: 36255488.
- Qureshi, S, Arani, N, Parvathareddy, V, Tchakarov, A, Abdelrahim, M, Suarez-Almazor, M, Zhang, J, Gibbons, DL, Heymach, JV, Altan, M, Abudayyeh, A. Case Report. Frontiers in Nephrology 3, 2023. e-Pub 2023. PMID: 37675380.
- Qureshi S, Arani N, Parvathareddy V, Tchakarov A, Abdelrahim M, Suarez-Almazor M, Zhang J, Gibbons DL, Heymach J, Altan M, Abudayyeh A. Case Report: Immune checkpoint inhibitor-induced multiorgan vasculitis successfully treated with rituximab. Front Nephrol 3:1168614, 2023. e-Pub 2023. PMID: 37675380.
- Jhaveri KD, Kitchlu A, Abudayyeh A. Does treating with anti-PD-1 to improve glomerular health come without a cost?. J Clin Invest 132(22), 2022. e-Pub 2022. PMID: 36377662.
- Abudayyeh A, Suo L, Lin H, Mamlouk O, Abdel-Wahab N, Tchakarov A. Pathologic Predictors of Response to Treatment of Immune Checkpoint Inhibitor-Induced Kidney Injury. Cancers (Basel) 14(21), 2022. e-Pub 2022. PMID: 36358686.
- Gupta S, Strohbehn IA, Wang Q, Hanna PE, Seethapathy R, Prosek JM, Herrmann SM, Abudayyeh A, Malik AB, Loew S, Carlos CA, Chang WT, Beckerman P, Mithani Z, Shah CV, Renaghan AD, de Seigneux S, Campedel L, Kitchlu A, Shin DS, Coppock G, Lumlertgul N, Garcia P, Ortiz-Melo DI, Rashidi A, Sprangers B, Aggarwal V, Benesova K, Jhaveri KD, Cortazar FB, Weins A, Zuo Y, Mooradian MJ, Reynolds KL, Leaf DE, Sise ME, Consortium I. Acute kidney injury in patients receiving pembrolizumab combination therapy versus pembrolizumab monotherapy for advanced lung cancer. Kidney Int 102(4):930-935, 2022. e-Pub 2022. PMID: 35964800.
- Gupta S, Garcia-Carro C, Prosek JM, Glezerman I, Herrmann SM, Garcia P, Abudayyeh A, Lumlertgul N, Malik AB, Loew S, Beckerman P, Renaghan AD, Carlos CA, Rashidi A, Mithani Z, Deshpande P, Rangarajan S, Shah CV, Seigneux S, Campedel L, Kitchlu A, Shin DS, Coppock G, Ortiz-Melo DI, Sprangers B, Aggarwal V, Benesova K, Wanchoo R, Murakami N, Cortazar FB, Reynolds KL, Sise ME, Soler MJ, Leaf DE, Investigators IC. Shorter versus longer corticosteroid duration and recurrent immune checkpoint inhibitor-associated AKI. J Immunother Cancer 10(9), 2022. e-Pub 2022. PMID: 36137651.
- Abdelrahim M, Esmail A, Umoru G, Westhart K, Abudayyeh A, Saharia A, Ghobrial RM. Immunotherapy as a Neoadjuvant Therapy for a Patient with Hepatocellular Carcinoma in the Pretransplant Setting: A Case Report. Curr Oncol 29(6):4267-4273, 2022. e-Pub 2022. PMID: 35735450.
- Abdelrahim M, Al-Rawi H, Esmail A, Xu J, Umoru G, Ibnshamsah F, Abudayyeh A, Victor D, Saharia A, McMillan R, Al Najjar E, Bugazia D, Al-Rawi M, Ghobrial RM. Gemcitabine and Cisplatin as Neo-Adjuvant for Cholangiocarcinoma Patients Prior to Liver Transplantation: Case-Series. Curr Oncol 29(5):3585-3594, 2022. e-Pub 2022. PMID: 35621680.
- Abdelrahim M, Esmail A, Xu J, Umoru G, Al-Rawi H, Saharia A, Abudayyeh A, Victor D, McMillan R, Kodali S, Ghobrial RM. Gemcitabine Plus Cisplatin Versus Non-Gemcitabine and Cisplatin Regimens as Neoadjuvant Treatment for Cholangiocarcinoma Patients Prior to Liver Transplantation: An Institution Experience. Front Oncol 12:908687, 2022. e-Pub 2022. PMID: 35719974.
- Gupta S, Short SAP, Sise ME, Prosek JM, Madhavan SM, Soler MJ, Ostermann M, Herrmann SM, Abudayyeh A, Anand S, Glezerman I, Motwani SS, Murakami N, Wanchoo R, Ortiz-Melo DI, Rashidi A, Sprangers B, Aggarwal V, Malik AB, Loew S, Carlos CA, Chang WT, Beckerman P, Mithani Z, Shah CV, Renaghan AD, Seigneux S, Campedel L, Kitchlu A, Shin DS, Rangarajan S, Deshpande P, Coppock G, Eijgelsheim M, Seethapathy H, Lee MD, Strohbehn IA, Owen DH, Husain M, Garcia-Carro C, Bermejo S, Lumlertgul N, Seylanova N, Flanders L, Isik B, Mamlouk O, Lin JS, Garcia P, Kaghazchi A, Khanin Y, Kansal SK, Wauters E, Chandra S, Schmidt-Ott KM, Hsu RK, Tio MC, Sarvode Mothi S, Singh H, Schrag D, Jhaveri KD, Reynolds KL, Cortazar FB, Leaf DE, Investigators IC. Acute kidney injury in patients treated with immune checkpoint inhibitors. J Immunother Cancer 9(10), 2021. e-Pub 2021. PMID: 34625513.
- Olson A, Lin R, Marin D, Rafei H, Bdaiwi MH, Thall PF, Basar R, Abudayyeh A, Banerjee P, Aung FM, Kaur I, Abueg G, Rao S, Chemaly R, Mulanovich V, Al-Atrash G, Alousi AM, Andersson BS, Anderlini P, Bashir Q, Castro KM, Daher M, Galvan IM, Hosing C, Im JS, Jones RB, Kebriaei P, Khouri I, Mehta R, Molldrem J, Nieto Y, Oran B, Popat U, Qazilbash M, Rondon G, Saini N, Spencer B, Srour S, Washington D, Barnett M, Champlin RE, Shpall EJ, Rezvani K. Third-Party BK Virus-Specific Cytotoxic T Lymphocyte Therapy for Hemorrhagic Cystitis Following Allotransplantation. J Clin Oncol 39(24):2710-2719, 2021. e-Pub 2021. PMID: 33929874.
- Abdelrahim M, Mamlouk O, Lin H, Lin J, Page V, Abdel-Wahab N, Swan J, Selamet U, Yee C, Diab A, Suki W, Abudayyeh A. Incidence, predictors, and survival impact of acute kidney injury in patients with melanoma treated with immune checkpoint inhibitors: a 10-year single-institution analysis. Oncoimmunology 10(1):1927313, 2021. e-Pub 2021. PMID: 34104543.
- Lin JS, Mamlouk O, Selamet U, Tchakarov A, Glass WF, Sheth RA, Layman RM, Dadu R, Abdelwahab N, Abdelrahim M, Diab A, Yee C, Abudayyeh A. Infliximab for the treatment of patients with checkpoint inhibitor-associated acute tubular interstitial nephritis. Oncoimmunology 10(1):1877415, 2021. e-Pub 2021. PMID: 33643693.
- Saberian C, Abdel-Wahab N, Abudayyeh A, Rafei H, Joseph J, Rondon G, Whited L, Gruschkus S, Fa'ak F, Daher M, Knape C, Safa H, Shoukier M, Suarez-Almazor ME, Marcotulli M, Ludford K, Gulbis AM, Konopleva M, Ohanian M, Ravandi F, Garcia-Manero G, Oran B, Popat UR, Mehta R, Alousi AM, Daver N, Champlin R, Diab A, Al-Atrash G. Post-transplantation cyclophosphamide reduces the incidence of acute graft-versus-host disease in patients with acute myeloid leukemia/myelodysplastic syndromes who receive immune checkpoint inhibitors after allogeneic hematopoietic stem cell transplantation. J Immunother Cancer 9(2), 2021. e-Pub 2021. PMID: 33637601.
- Murakami N, Mulvaney P, Danesh M, Abudayyeh A, Diab A, Abdel-Wahab N, Abdelrahim M, Khairallah P, Shirazian S, Kukla A, Owoyemi IO, Alhamad T, Husami S, Menon M, Santeusanio A, Blosser C, Zuniga SC, Soler MJ, Moreso F, Mithani Z, Ortiz-Melo D, Jaimes EA, Gutgarts V, Lum E, Danovitch GM, Cardarelli F, Drews RE, Bassil C, Swank JL, Westphal S, Mannon RB, Shirai K, Kitchlu A, Ong S, Machado SM, Mothi SS, Ott PA, Rahma O, Hodi FS, Sise ME, Gupta S, Leaf DE, Devoe CE, Wanchoo R, Nair VV, Schmults CD, Hanna GJ, Sprangers B, Riella LV, Jhaveri KD, Transplant Consortium ICIISO. A multi-center study on safety and efficacy of immune checkpoint inhibitors in cancer patients with kidney transplant. Kidney Int. e-Pub 2020. PMID: 33359528.
- Lin JS, Wang DY, Mamlouk O, Glass WF, Abdelrahim M, Yee C, Abudayyeh A. Immune checkpoint inhibitor associated reactivation of primary membranous nephropathy responsive to rituximab. J Immunother Cancer 8(2), 2020. e-Pub 2020. PMID: 33020246.
- Abudayyeh A, Song J, Abdelrahim M, Dahbour I, Page VD, Zhou S, Shen C, Zhao B, Pai RN, Amaram-Davila J, Manzano JG, George MC, Yennu S, Mandayam SA, Nates JL, Moss AH. Renal Replacement Therapy in Patients With Stage IV Cancer Admitted to the Intensive Care Unit With Acute Kidney Injury at a Comprehensive Cancer Center Was Not Associated With Survival. Am J Hosp Palliat Care 37(9):1049909120902115, 2020. e-Pub 2020. PMID: 31986903.
- Abudayyeh A, Lin H, Mamlouk O, Abdelrahim M, Saliba R, Rondon G, Martinez CS, Delgado R, Page V, Rajasekaran A, Sanders PW, Qazilbash M. Impact of autologous stem cell transplantation on long term renal function and associated progression-free and overall survival in multiple myeloma. Leuk Lymphoma:1-11. e-Pub 2020. PMID: 32723196.
- Mamlouk O, Lin JS, Abdelrahim M, Tchakarov AS, Glass WF, Selamet U, Buni M, Abdel-Wahab N, Abudayyeh A. Checkpoint inhibitor-related renal vasculitis and use of rituximab. J Immunother Cancer 8(2), 2020. e-Pub 2020. PMID: 32718987.
- Abudayyeh A, Lin H, Abdelrahim M, Rondon G, Andersson BS, Martinez CS, Page VD, Tarrand JJ, Kontoyiannis DP, Marin D, Oran B, Olson A, Jones R, Popat U, Champlin RE, Chemaly RF, Shpall EJ, Rezvani K. Development and validation of a risk assessment tool for BKPyV Replication in allogeneic stem cell transplant recipients. Transpl Infect Dis:e13395. e-Pub 2020. PMID: 32602954.
- Abdelrahim M, Marina G, Amir H, William FG, Abudayyeh A. Acute Renal Failure Due to Vitamin C: Case Report and Review of the Literature. Journal of Cancer & Oncology, 2020. e-Pub 2020.
- Cortazar FB, Kibbelaar ZA, Glezerman IG, Abudayyeh A, Mamlouk O, Motwani SS, Murakami N, Herrmann SM, Manohar S, Shirali AC, Kitchlu A, Shirazian S, Assal A, Vijayan A, Renaghan AD, Ortiz-Melo DI, Rangarajan S, Malik AB, Hogan JJ, Dinh AR, Shin DS, Marrone KA, Mithani Z, Johnson DB, Hosseini A, Uprety D, Sharma S, Gupta S, Reynolds KL, Sise ME, Leaf DE. Clinical Features and Outcomes of Immune Checkpoint Inhibitor-Associated AKI: A Multicenter Study. J Am Soc Nephrol 31(2):435-446, 2020. e-Pub 2020. PMID: 31896554.
- Strati P, Abdelrahim M, Selamet U, Page VD, Pierce SA, Verstovsek S, Abudayyeh A. Ruxolitinib therapy is associated with improved renal function in patients with primary myelofibrosis. Ann Hematol 98(7):1611-1616, 2019. e-Pub 2019. PMID: 31093708.
- Abdel-Wahab N, Safa H, Abudayyeh A, Johnson DH, Trinh VA, Zobniw CM, Lin H, Wong MK, Abdelrahim M, Gaber AO, Suarez-Almazor ME, Diab A. Corrections to: Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients: an institutional experience and a systematic review of the literature. J Immunother Cancer 7(1):158, 2019. e-Pub 2019. PMID: 31234936.
- Strati P, Glass WF, Abdelrahim M, Selamet U, Tchakarov A, Workeneh BT, Verstovsek S, Abudayyeh A. Renal complications of primary myelofibrosis. Leuk Lymphoma 60(2):1-4, 2019. e-Pub 2019. PMID: 29966471.
- Mamlouk O, Selamet U, Machado S, Abdelrahim M, Glass WF, Tchakarov A, Gaber L, Lahoti A, Workeneh B, Chen S, Lin J, Abdel-Wahab N, Tayar J, Lu H, Suarez-Almazor M, Tannir N, Yee C, Diab A, Abudayyeh A. Nephrotoxicity of immune checkpoint inhibitors beyond tubulointerstitial nephritis: single-center experience. J Immunother Cancer 7(1):2, 2019. e-Pub 2019. PMID: 30612580.
- Kala J, Abudayyeh A. Magnesium: An Overlooked Electrolyte. J Emerg Med 52(5):741-743, 2017. e-Pub 2017. PMID: 28222929.
- Abudayyeh A, Hamdi A, Abdelrahim M, Lin H, Page VD, Rondon G, Andersson BS, Afrough A, Martinez CS, Tarrand JJ, Kontoyiannis DP, Marin D, Gaber AO, Oran B, Chemaly RF, Ahmed S, Abudayyeh I, Olson A, Jones R, Popat U, Champlin RE, Shpall EJ, Rezvani K. Poor immune reconstitution is associated with symptomatic BK polyomavirus viruria in allogeneic stem cell transplant recipients. Transpl Infect Dis 19(1), 2017. e-Pub 2017. PMID: 27862740.
- Ertem FU, Zhang W, Chang K, Mohaiza Dashwood W, Rajendran P, Sun D, Abudayyeh A, Vilar E, Abdelrahim M, Dashwood RH. Oncogenic targets Mmp7, S100a9, Nppb and Aldh1a3 from transcriptome profiling of FAP and Pirc adenomas are downregulated in response to tumor suppression by Clotam. Int J Cancer 140(2):460-468, 2017. e-Pub 2017. PMID: 27706811.
- Oliver N, Luong T, Tchakarov A, Abdelrahim M, Mulanovich VE, Kontoyiannis DP, Jones R, Kebriaei P, Samuels J, Glass W, Abudayyeh A. Disseminated cryptococcal infection in allogeneic stem cell transplant patients: a rare cause of acute kidney injury. Bone Marrow Transplant 51(10):1301-1304, 2016. e-Pub 2016. PMID: 27159179.
- Abudayyeh A, Hamdi A, Lin H, Abdelrahim M, Rondon G, Andersson BS, Afrough A, Martinez CS, Tarrand JJ, Kontoyiannis DP, Marin D, Gaber AO, Salahudeen A, Oran B, Chemaly RF, Olson A, Jones R, Popat U, Champlin RE, Shpall EJ, Winkelmayer WC, Rezvani K. Symptomatic BK Virus Infection Is Associated with Kidney Function Decline and Poor Overall Survival in Allogeneic Hematopoietic Stem Cell Recipients. Am J Transplant 16(5):1492-502, 2016. e-Pub 2016. PMID: 26608093.
- Safe S, Jin UH, Morpurgo B, Abudayyeh A, Singh M, Tjalkens RB. Nuclear receptor 4A (NR4A) family - orphans no more. J Steroid Biochem Mol Biol 157:48-60, 2016. e-Pub 2016. PMID: 25917081.
- Rajasekaran A, Ngo TT, Abdelrahim M, Glass W, Podoll A, Verstovsek S, Abudayyeh A. Primary myelofibrosis associated glomerulopathy: significant improvement after therapy with ruxolitinib. BMC Nephrol 16:121, 2015. e-Pub 2015. PMID: 26232031.
- Abudayyeh A, Truong LD, Beck LH, Weber DM, Rezvani K, Abdelrahim M. Membranous nephropathy in autologous hematopoietic stem cell transplant: autologous graft-versus-host disease or autoimmunity induction?. Clin Kidney J 8(4):440-4, 2015. e-Pub 2015. PMID: 26251713.
- Hedrick E, Lee SO, Kim G, Abdelrahim M, Jin UH, Safe S, Abudayyeh A. Nuclear Receptor 4A1 (NR4A1) as a Drug Target for Renal Cell Adenocarcinoma. PLoS One 10(6):e0128308, 2015. e-Pub 2015. PMID: 26035713.
- Nair V, Sreevalsan S, Basha R, Abdelrahim M, Abudayyeh A, Rodrigues Hoffman A, Safe S. Mechanism of Metformin-dependent Inhibition of mTOR and Ras Activity in Pancreatic Cancer: Role of Sp Transcription Factors. J Biol Chem 289(40):27692-701, 2014. e-Pub 2014. PMID: 25143389.
- Abudayyeh AA, Lahoti A, Salahudeen AK. Onconephrology: the need and the emergence of a subspecialty in nephrology. Kidney Int 85(5):1002-4, 2014. e-Pub 2014. PMID: 24786870.
- Maliakal P, Abdelrahim M, Sankpal UT, Maliakal C, Baker CH, Safe S, Herrera LJ, Abudayyeh A, Kaja S, Basha R. Chemopreventive effects of tolfenamic acid against esophageal tumorigenesis in rats. Invest New Drugs 30(3):853-61, 2012. e-Pub 2012. PMID: 21197621.
- Colon J, Basha MR, Madero-Visbal R, Konduri S, Baker CH, Herrera LJ, Safe S, Sheikh-Hamad D, Abudayyeh A, Alvarado B, Abdelrahim M. Tolfenamic acid decreases c-Met expression through Sp proteins degradation and inhibits lung cancer cells growth and tumor formation in orthotopic mice. Invest New Drugs 29(1):41-51, 2011. e-Pub 2011. PMID: 19851711.
- Papineni S, Chintharlapalli S, Abdelrahim M, Lee SO, Burghardt R, Abudayyeh A, Baker C, Herrera L, Safe S. Tolfenamic acid inhibits esophageal cancer through repression of specificity proteins and c-Met. Carcinogenesis 30(7):1193-201, 2009. e-Pub 2009. PMID: 19406933.
- Liu X, Abdelrahim M, Abudayyeh A, Lei P, Safe S. The nonsteroidal anti-inflammatory drug tolfenamic acid inhibits BT474 and SKBR3 breast cancer cell and tumor growth by repressing erbB2 expression. Mol Cancer Ther 8(5):1207-17, 2009. e-Pub 2009. PMID: 19435870.
- Konduri S, Colon J, Baker CH, Safe S, Abbruzzese JL, Abudayyeh A, Basha MR, Abdelrahim M. Tolfenamic acid enhances pancreatic cancer cell and tumor response to radiation therapy by inhibiting survivin protein expression. Mol Cancer Ther 8(3):533-42, 2009. e-Pub 2009. PMID: 19258429.
- Cho SD, Chintharlapalli S, Abdelrahim M, Papineni S, Liu S, Guo J, Lei P, Abudayyeh A, Safe S. 5,5'-Dibromo-bis(3'-indolyl)methane induces Kruppel-like factor 4 and p21 in colon cancer cells. Mol Cancer Ther 7(7):2109-20, 2008. e-Pub 2008. PMID: 18645021.
- Abdelrahim, M, Safe, S, Baker, C, Abudayyeh, A. RNAi and Cancer: implications and application. J RNAi Gene Silencing 2(1):136-45, 2006. e-Pub 2006.
- Alasadi Y, Garcia JC, Arani N, Page V, Geng Y, Andersen CR, Tchakarov A, Kitchlu A, Mamlouk O, Abudayyeh A. Rituximab for the treatment of immune checkpoint inhibitor–induced glomerulonephritis. Clinical Kidney Journal.
Invited Articles
- Abudayyeh A, Hingorani S, Jhaveri K. UpToDate- Kidney disease following hematopoietic cell transplantation. UpToDate, 2021. e-Pub 2021.
- Henriksen KJ, Hogan JJ, Abudayyeh A, Mistry N, Koyner JL, Jhaveri KD. Case-based discussions in onco-nephrology. Journal of Onconephrology, 2020. e-Pub 2020.
- Abdelrahim M, Abudayyeh A. Renal Toxicity. Immunotherapy Adv Exp Med Biol, 2020. e-Pub 2020.
- Abudayyeh A. Onconephrology: An Evolving Field. Methodist Debakey Cardiovasc J 15(4):305-307, 2019. e-Pub 2019. PMID: 31988693.
- Mamlouok M, Abudayyeh A. Cancer immunotherapy and its renal effects. Journal of Onco-Nephrology. e-Pub 2019.
- Selamet U, Abudayyeh A. Chronic Kidney Disease as a Complication of Cancer. Journal of Onconephrology, 2017. e-Pub 2017.
- Finkel KW, Cohen EP, Shirali A, Abudayyeh A, Onco-Nephrology Forum ASON. Paraprotein-related Kidney Disease: Evaluation and Treatment of Myeloma Cast Nephropathy. Clin J Am Soc Nephrol 11(12):2273-2279, 2016. e-Pub 2016. PMID: 27526708.
- Abudayyeh A, Abdelrahim M. Current Strategies for Prevention and Management of Stem Cell Transplant Related Urinary Tract and Voiding Dysfunction. Current Bladder Dysfunction Reports, 2015. e-Pub 2015.
Review Articles
- Alasadi, Y, Garcia, JC, Arani, N, Page, VD, Geng, Y, Andersen, C, Tchakarov, A, Kitchlu, A, Mamlouk, O, Abudayyeh, A. Rituximab for the treatment of immune checkpoint inhibitor–induced glomerulonephritis. Clinical Kidney Journal 19(1), 2026. e-Pub 2026. PMID: 41788614.
- Youssef N, Abudayyeh A. Immune Checkpoint Inhibitor-Related Acute Kidney Injury: Management and Challenges. Am J Nephrol:1-12, 2025. e-Pub 2025. PMID: 39773560.
- Esmail, A, Badheeb, M, Alnahar, B, Almiqlash, B, Sakr, Y, Al Najjar, E, Awas, A, Alsayed, M, Khasawneh, B, Alkhulaifawi, M, Alsaleh, A, Abudayyeh, A, Rayyan, Y, Abdelrahim, M. The Recent Trends of Systemic Treatments and Locoregional Therapies for Cholangiocarcinoma. Pharmaceuticals 17(7), 2024. e-Pub 2024. PMID: 39065760.
- Esmail, A, Badheeb, M, Alnahar, B, Almiqlash, B, Sakr, Y, Al Najjar, E, Awas, A, Alsayed, M, Khasawneh, B, Alkhulaifawi, M, Alsaleh, A, Abudayyeh, A, Rayyan, Y, Abdelrahim, M. The Recent Trends of Systemic Treatments and Locoregional Therapies for Cholangiocarcinoma. Pharmaceuticals 17(7), 2024. e-Pub 2024. PMID: 39065760.
- Esmail, A, Badheeb, M, Alnahar, B, Almiqlash, B, Sakr, Y, Khasawneh, B, Al Najjar, E, Al-Rawi, H, Abudayyeh, A, Rayyan, Y, Abdelrahim, M. Cholangiocarcinoma. Cancers 16(11), 2024. e-Pub 2024. PMID: 38893067.
- Bugazia, D, Al Najjar, E, Esmail, A, Abdelrahim, S, Abboud, K, Abdelrahim, A, Umoru, G, Rayyan, HA, Abudayyeh, A, Al Moustafa, AE, Abdelrahim, M. Pancreatic ductal adenocarcinoma. Frontiers in Oncology 14, 2024. e-Pub 2024. PMID: 39011469.
- Abdelrahim, M, Esmail, A, Abudayyeh, A, Murakami, N, Victor, DW, Kodali, S, Cheah, YL, Simon, CJ, Noureddin, M, Connor, AA, Saharia, A, Moore, LW, Heyne, K, Kaseb, A, Gaber, AO, Ghobrial, RM. Transplant Oncology. Cancers 15(22), 2023. e-Pub 2023. PMID: 38001597.
- Abboud K, Umoru G, Esmail A, Abudayyeh A, Murakami N, Al-Shamsi HO, Javle M, Saharia A, Connor AA, Kodali S, Ghobrial RM, Abdelrahim M. Immune Checkpoint Inhibitors for Solid Tumors in the Adjuvant Setting: Current Progress, Future Directions, and Role in Transplant Oncology. Cancers (Basel) 15(5), 2023. e-Pub 2023. PMID: 36900226.
- Badheeb M, Abdelrahim A, Esmail A, Umoru G, Abboud K, Al-Najjar E, Rasheed G, Alkhulaifawi M, Abudayyeh A, Abdelrahim M. Pancreatic Tumorigenesis: Precursors, Genetic Risk Factors and Screening. Curr Oncol 29(11):8693-8719, 2022. e-Pub 2022. PMID: 36421339.
- Gudsoorkar, P, Abudayyeh, A, Tchakarov, A, Hanna, R. Onconephrology and Thrombotic Microangiopathy. Seminars in Nephrology 42(6), 2022. e-Pub 2022. PMID: 37196461.
- Kawashima, S, Joachim, K, Abdelrahim, M, Abudayyeh, A, Jhaveri, KD, Murakami, N. Immune checkpoint inhibitors for solid organ transplant recipients. Korean Journal of Transplantation 36(2):82-98, 2022. e-Pub 2022. PMID: 35919193.
- Abdelrahim M, Esmail A, Saharia A, Abudayyeh A, Abdel-Wahab N, Diab A, Murakami N, Kaseb AO, Chang JC, Gaber AO, Ghobrial RM. Utilization of Immunotherapy for the Treatment of Hepatocellular Carcinoma in the Peri-Transplant Setting: Transplant Oncology View. Cancers (Basel) 14(7), 2022. e-Pub 2022. PMID: 35406533.
- Abudayyeh A, Wanchoo R. Kidney Disease Following Hematopoietic Stem Cell Transplantation. Adv Chronic Kidney Dis 29(2):103-115.e1, 2022. e-Pub 2022. PMID: 35817518.
- Schreiber B, Abdelrahim M, Abudayyeh A, Murakami N. Emerging Concepts in Managing Malignancy in Kidney Transplant Patients. Semin Nephrol 42(1):63-75, 2022. e-Pub 2022. PMID: 35618396.
- Abdelrahim M, Esmail A, Abudayyeh A, Murakami N, Saharia A, McMillan R, Victor D, Kodali S, Shetty A, Nolte Fong JV, Moore LW, Heyne K, Gaber AO, Ghobrial RM. Transplant Oncology: An Evolving Field in Cancer Care. Cancers (Basel) 13(19), 2021. e-Pub 2021. PMID: 34638395.
- Sprangers B, Abudayyeh A, Latcha S, Perazella MA, Jhaveri KD. How to determine kidney function in cancer patients?. Eur J Cancer 132:141-149. e-Pub 2020. PMID: 32361629.
- Abdelrahim M, Abudayyeh A. Renal Toxicity. Adv Exp Med Biol 1244:287-293, 2020. e-Pub 2020. PMID: 32301023.
- Wanchoo R, Abudayyeh A, Doshi M, Edeani A, Glezerman IG, Monga D, Rosner M, Jhaveri KD. Renal toxicities of novel agents used for treatment of multiple myeloma. Clin J Am Soc Nephrol 12(1):176-189, 2017. e-Pub 2017. PMID: 27654928.
Professional Educational Materials
- Abudayyeh A, Hingorani S, Jhaveri K. UptoDate-Kidney disease following hematopoietic cell transplantation. UptoDate.
Other Articles
- Selamet U, Joachim K, Lin H, Rondon G, Martinez CS, Delgado R, Page V, Motwani SS, Dincer B, Bianchi G, Qazilbash M, Murakami N, Abudayyeh A The Association of Kidney Function on Survival in Patients with AL Amyloidosis after Autologous Stem Cell Transplantation: A Multicenter Study, 2025. PMID: 41212634.
- Olson A, Li YE, Basar R, Banerjee P, Kaur I, Abueg G, Sylejmani M, Uprety N, Shrestha R, Silva FR, Page V, Champlin RE, Kontoyiannis DP, Chemaly RF, Shpall EJ, Moore L, Gaber OA, Rezvani K, Abudayyeh A Role of BK virus CTLs in the treatment of BK virus –associated nephropathy in kidney-transplant and hematopoietic cell transplant recipients. Transplant Infectious Disease-In Press.
- Youssef N, Habeeb M, Chen H, Alhamal Z, Mamlouk O, Lin H, Page V, Tchakarov A, Basu S, Diab A, Sharma P, Abudayyeh A Infliximab for Grade III or IV Immune Checkpoint Inhibitor Nephritis Clinical and Translational Evidence. KI Reports.
Editorials
- Abudayyeh, A, Karam, S. Editorial. Frontiers in Nephrology 3, 2023. PMID: 37675366.
- Abudayyeh A, Karam S. Editorial: Women in onconephrology: 2022. Front Nephrol 3:1240195, 2023. PMID: 37675366.
Abstracts
- Lin JS, Wang DY, Mamlouk O, Glass WF, Abudayyeh A. Immune Checkpoint Inhibitor Associated Reactivation of Primary Membranous Nephropathy Responsive to Rituximab. American Society of nephrology-Kidney Week, 2020. e-Pub 2020.
- Montanez M, Lin JS, Mamlouk O, Glass WF, Abudayyeh A. Immune Checkpoint Inhibitor Induced p-ANCA Multiorgan Vasculitis. American Society of Nephrology-Kidney week, 2020. e-Pub 2020.
- Lin JS, Mamlouk O, Glass WF, Abudayyeh A. Immune Checkpoint Inhibitor Induced Kidney and Cardiac Sarcoidosis,. American Society of nephrology-Kidney Week, 2020. e-Pub 2020.
- Abudayyeh A, Abdelrahim M, Fossella AF. Use of pulse steroids to treat renal IRAE to maintain patients with metastatic non-small cell carcinoma cancer on pembrolizumab. ASCO, 2020. e-Pub 2020.
- Abudayyeh A. Incidence of AKI in a large retrospective cancer cohort using Checkpoint Inhibitors. ASN’s 2018 Abstract Supplement, 2019. e-Pub 2019.
- Abudayyeh A. Impact of autologous SCT in myeloma patients on Renal Function, Progression Free Survival and Overall Survival: A longitudinal Analysis. ASN, 2019. e-Pub 2019.
- Abudayyeh A. Incidence of AKI in Melanoma patients treated with Immune Checkpoint Inhibitors. ASN, 2019. e-Pub 2019.
- Abudayyeh A, Song J, Abdelrahim M, Page VD, Mandayam SA, Nates JL, Moss AH. Dialysis does not affect outcomes in stage IV cancer patients admitted to the intensive care unit with acute kidney injury at a Comprehensive Cancer Center. ASN, 2019. e-Pub 2019.
- Abudayyeh A. Allo-immunity and graft rejection after checkpoint inhibitor therapy (CPI) in solid organ transplant (SOT) recipients. ASCO June 2018, Chicago, Ill. USA, 2018. e-Pub 2018.
- Abudayyeh A. Development and validation of a risk assessment tool for symptomatic BKV infection. ASCO June 2018, Chicago , Ill. USA, 2018. e-Pub 2018.
- Strati P, Abdelrahim M, Selamet U, Page VD, Pierce SA, Verstovsek S, Abudayyeh A. Ruxolitinib Therapy Improves Renal Function in Patients with Primary Myelofibrosis. Haematologica, 2018. e-Pub 2018.
- Abudayyeh A, Abdelrahim M, Selamet U, Workeneh BT, Machado S, Lahoti A, Glass WF, Tchakarov A, Tannir NM, Abdel-Wahab N, Diab A. Checkpoint inhibitor induced glomerulonephritis. J Clin Oncol 36, 2018. e-Pub 2018.
- Abudayyeh A. Checkpoint Inhibitor Therapy in Solid Organ and Allogeneic Stem Cell Transplantation: Data Mining of The Truven Health Marketscan Research Database. SITC 33rd Annual Meeting, Walter E Washington Convention Center , Wash DC Nov 9-11,2018, 2018. e-Pub 2018.
- Abudayyeh A, Abdelrahim M, Selamet U, Workeneh BT, Machado S, Lahoti A, Glass WF, Tchakarov A, Tannir NM, Abdel-Wahab N, Diab A. Checkpoint inhibitor induced glomerulonephritis. ASCO 2017, 2017. e-Pub 2017.
- Selamet U, Ziaolhagh A, Lakhani LS, Lahoti A, Workeneh BT, Tchakarov A, Glass WF, Abudayyeh A. Nephrotoxicity of Immune Checkpoint Inhibitors: MD Anderson Cancer Center’s Experience. J Am Soc Nephrol 28:404, 2017. e-Pub 2017.
- Ziaolhagh A, Selamet U, Lakhani LS, Tchakarov A, Glass WF, Abudayyeh A. Renal Complications of Hematopoietic Stem Cell Transplantation (SCT) and Glomerulopathies in Patients with Leukemia Receiving SCT: MD Anderson Cancer Center’s Experience. J Am Soc Nephrol 28:1096, 2017. e-Pub 2017.
- Lakhani LS, Selamet U, Ziaolhagh A, Glass WF, Tchakarov A, Abudayyeh A. Renal biopsy results from patients with Multiple Myeloma-data from a Comprehensive National Cancer Institute: A 10 year MD Anderson Experience. J Am Soc Nephrol 28:768, 2017. e-Pub 2017.
- Ziaolhagh A, Selamet U, Glass WF, Tchakarov A, Abudayyeh A. A Rare Case of Secondary Amyloidosis with Kidney and Colon involvement in Chordoma. J Am Soc Nephrol 28:191, 2017. e-Pub 2017.
- Ziaolhagh A, Selamet U, Abudayyeh A. Paraneoplastic Glomerulonephritis: An Indication to Treat Low Grade Lymphoma. Am J Kidney 69(4):A105, 2017. e-Pub 2017.
- Ziaolhagh A, Selamet U, Abudayyeh A. Rituximab in Combination with High Dose Steroid for Treatment of Graft versus Host Disease of the Kidney after Hematopoietic Stem Cell Transplantation. Am J Kidney 69(4):A105, 2017. e-Pub 2017.
Book Chapters
- Abudayyeh, A, Diab, A, Tchakarov, A. Membranous Nephropathy Post Immune Checkpoint Inhibitors, 301-305, 2025.
- Qureshi, S, Arani, N, Suarez-Almazor, M, Tchakarov, A, Altan, M, Abudayyeh, A. Vasculitis Post Immune Checkpoint Inhibitors Therapy, 293-299, 2025.
- Abudayyeh, A, Tayar, JH, Tchakarov, A. Acute Tubulointerstitial Nephritis Post Immune Checkpoint Inhibitor Therapy, 287-292, 2025.
- Attieh, RM, Abudayyeh, A, Murakami, N. Immunotherapy and immunosuppressants, 149-155, 2024.
- Shivaraj, K, Abudayyeh, A, Gaber, AO. B. Immunotherapy and kidney transplant, 107-113, 2024.
- Abudayyeh, A, Perazella, MA. Oncology, 781-790.e2, 2023.
- Mamlouk, O, Lin, JS, Abudayyeh, A. Nephrology (Kidney), 197-214, 2022.
- Abdelrahim, M, Abudayyeh, A. Renal Toxicity, 389-397, 2021.
- Abudayyeh, A. Onco-Nephrology, 393-404, 2021.
- Abudayyeh A, Kalu C. Hematuria,Hemorrhagic cystitis & Obstructive Uropathy in the Cancer Patient. In: Oncologic Critical Care Textbook, 2020.
- Chukwuma K, Abudayyeh A. Hemorrhagic Cystitis in the Critically 2 Ill Cancer Patients. In: Oncological Critical Care. Springer, 2020.
- Selamet U, Hanna R, Rastogi A, Abudayyeh A. Chemotherapeutic Agents and the Kidney. In: Kidney Protection. Oxford University Press, 2019.
- Abudayyeh A, Abdelrahim M, Albiges L. Renal Toxicity Associated with Immune Checkpoint Inhibitors. In: SITC’s Guide to Managaing Immunotherapy Toxicity. Demos Medical Publishing - Springer Publishing, 171-84, 2019.
- Abdelrahim M, Nash MJ, Gottipolu S, Abudayyeh A, Basha R. Anticancer activity of a small molecule, tolfenamic acid: an emphasis on pancreatic cancer. In: Theranostic Approach for Pancreatic Cancer. Elsevier, 195-210, 2019.
- Selamet U, Abudayyeh A. Dysnatremias in Cancer. In: OncoNephrology. Elsevier Inc, 9, 2019.
- Selamet U, Hanna R, Rastogi A, Abudayyeh A. Chemotherapeutic Agents and the Kidney. In: Renal Protection. Oxford University Press, 2018.
- ASanford R, Abudayyeh A, Logothetis CJ, Tannir N. Urologic Complications (Chapter 129). In: Cancer Medicine, 9th edition, 2018.
- Abudayyeh A. Hyponatremia in cancer. In: Onconephrology, 2018.
- Sanders P, Abudayyeh A. Dysproteinemias and Amyloidosis. In: National Kidney Foundation Primer in Kidney Diseases, 2017.
- Abudayyeh A, APerazella M. Onco-Nephrology: Kidney Disease in Cancer Patients. In: Comprehensive Clinical Nephrology 6th edition. 6, 2017.
- Abudayyeh A, Finkel K. Hematological complications. In: Disorders and Kidney Disease. American Society of Nephrology. Onco-Nephrology Core Curriculum. American Society of Nephrology, 2015.
- Jhaveri K, Salahudeen AK. Onco-Nephrology: Cancer, Chemotherapy and the Kidney. In: Obstruction. Springer, 2015.
- Floege J, Johnson RJ, Feehally J. Comprehensive Clinical Nephrology . In: Renal Disease and Cancer. 5th, 2014.
- Zakaria A. Renal Diseases. In: Neurocritical Care Board Review. Demos Medical Publishing, 2013.
- Finkel KW, Howard SC. Renal disease in cancer patients. In: electrolyte abnormailities. Elsevier Academic Press, 2013.
Letters to the Editor
- Siricilla M, Abdelrahim M, Abudayyeh A. Use of Tolvaptan Beyond Thirty Days in a Case of Refractory SIADH. Journal of Nephrology and Therapeutics, 2016.
Patient Reviews
CV information above last modified July 22, 2026